China Pharmaceuticals and Healthcare Report Q2 2014 - NBC12.com - Richmond, VA News

China Pharmaceuticals and Healthcare Report Q2 2014

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE ReportBuyer



 

LONDON, May 13, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

China Pharmaceuticals and Healthcare Report Q2 2014

http://www.reportbuyer.com/pharma_healthcare/therapeutic/china_pharmaceuticals_healthcare_report_q2_2013.html


Includes 3 FREE quarterly updates

BMI View: Strong sales growth reported by multinational pharmaceutical firms in China over the course
of 2013 is directly in line with our longterm
optimism towards the country's pharmaceutical and healthcare market. We continue to maintain this vi
ew, in light of supportive government policies and positive population dynamics.

Headline Expenditure Projections
- Pharmaceuticals: CNY532.4bn (US$86.6bn) in 2013 to CNY610.8bn (US$99.7bn) in 2014; +14.7% in
local currency and +15.1% in US dollar terms.
- Healthcare: CNY3,172.4bn (US$516.0bn) in 2013 to CNY3,601.5bn (US$587.8bn) in 2014; +13.5% in
local currency terms and +13.9% in US dollar terms.


Risk/Reward Rating: China's Pharmaceutical
Risk/Reward Rating (RRR) score for Q214 is 64.8 out of the
maximum 100 under our newly improved RRR system. The country scored above average for the majority
of the indicators and sub-indicators including overall market expenditure, sector value growth, patent
respect and policy continuity. China is ranked fifth, behind Japan, South Korea Australia and
Taiwan among the 19 key markets in Asia Pacific.
BMI Industry View 7
SWOT 9
Political . 11
Economic .. 12
Business Environment 13
Industry Forecast .. 14
Pharmaceutical Market Forecast . 14
Table: Pharmaceutical Sales Indicators, 2010-2018 16
Healthcare Market Forecast . 16
Table: Healthcare Expenditure Indicators 2010-2018 .. 18
Table: Healthcare Governmental Indicators 2010-2018 .18
Table: Healthcare Private Indicators 2010-2018 . 19
Prescription Drug Market Forecast 19
Table: Prescription Drug Sales Indicators, 2010-2018 .. 21
Patented Drug Market Forecast .. 21
Table: Patented Drug Market Indicators, 2010-2018 ..23
Generic Drug Market Forecast 24
Table: China Generic Drug Sales Indicators, 2010-2018 . . 25
OTC Medicine Market Forecast .. 26
Regulatory Regime 27
Table: OTC Medicine Sales Indicators 2010-2018 29
Pharmaceutical Trade Forecast .. 29
Table: China Pharmaceutical Trade Data And Forecasts (US$mn) 2010-2018 ..31
Table: China Pharmaceutical Trade Data And Forecasts (CNYmn) 2010-2018 .. . 31
Other Healthcare Data .. 31
Key Risks To BMI's Forecast Scenario 32
Macroeconomic Forecasts .. 35
Economic Analysis .. 35
Table: China - Economic Activity . 39
Industry Risk Reward Ratings 40
Asia Risk/Reward Ratings . 40
China Risk/Reward Ratings .. 46
Rewards .. 46
Risks . 46
Market Overview 48
Industry Trends And Developments .. 49
Epidemiology . 49
Table: Death Rate Of Major Diseases In Urban And Rural Areas (2012) .52
Healthcare Sector . 53
Research And Development . 61
Table: Selected List Of MNC With R&D Bases In China . . 61
Table: Selected List Of Collaboration In R&D Operations In China . 67
Clinical Trials 69
Biotechnology Sector 72
Regulatory Development .. 80
Regulatory Regime 80
Table: Important China GMP Deadlines . 84
Intellectual Property Issues . 85
Pricing Regime .. 90
Reimbursement Regime 99
Competitive Landscape .. 103
Pharmaceutical Industry .. 103
Table: Top 20 China / Hong Kong-Based Pharmaceutical Companies According To Market Capitalisation . 103
Pharmaceutical Wholesale 104
Recent Developments . 105
Traditional Chinese Medicine .. 113
Company Profile .. 116
Sinopharm .. 116
China Shijiazhuang Pharmaceutical Group 121
North China Pharmaceutical Corporation .. 124
Shanghai Pharmaceutical .. 127
GlaxoSmithKline .. 130
Pfizer .. 135
AstraZeneca .. 139
Merck KGaA . 145
Sanofi .. 148
Novartis .. 152
Roche .. 157
Eli Lilly .. 162
Merck & Co 166
Bayer Schering Pharma .. 170
Demographic Forecast 174
Table: China's Population By Age Group, 1990-2020 ('000) ..175
Table: China's Population By Age Group, 1990-2020 (% of total) 176
Table: China's Key Population Ratios, 1990-2020 . 177
Table: China's Rural And Urban Population, 1990-2020 . 177
Glossary 178
Methodology .. 180
Pharmaceutical Expenditure Forecast Model .. 180
Healthcare Expenditure Forecast Model 180
Notes On Methodology .. 181
Risk/Reward Ratings Methodology . 182
Ratings Overview 183
Table: Pharmaceutical Risk/Reward Ratings Indicators . . 183
Indicator Weightings . 184


Read the full report:
China Pharmaceuticals and Healthcare Report Q2 2014

http://www.reportbuyer.com/pharma_healthcare/therapeutic/china_pharmaceuticals_healthcare_report_q2_2013.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

 

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow